Trial Profile
Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2019
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms IRST 100.06
- 09 Mar 2012 New trial record